scholarly journals Impact of body mass index on compliance and persistence to adjuvant breast cancer therapy

The Breast ◽  
2012 ◽  
Vol 21 (4) ◽  
pp. 487-492 ◽  
Author(s):  
Seraina Margaretha Schmid ◽  
Monika Eichholzer ◽  
Florence Bovey ◽  
Mary Elizabeth Myrick ◽  
Andreas Schötzau ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Body Mass Index ◽  
Cancer Therapy ◽  
Body Mass ◽  
Breast Cancer Therapy ◽  
Adjuvant Breast Cancer

scholarly journals Specialized consultations in a hospital-based referral center for patients suspected of having limb lymphedema: Impact on diagnosis

2017 ◽  
Vol 22 (4) ◽  
pp. 331-336 ◽  
Author(s):  
Stéphane Vignes ◽  
Florence Vidal ◽  
Maria Arrault
Keyword(s):  
Breast Cancer ◽  
Body Mass Index ◽  
Cancer Therapy ◽  
Body Mass ◽  
Upper Limb ◽  
Symptom Onset ◽  
Lower Limb ◽  
Breast Cancer Therapy ◽  
Entire Cohort ◽  
Referral Center

Lymphedema, a chronic debilitating disease, is not always easily diagnosed. A total of 254 new patients ((217 women, 37 men), median (Q1–Q3) age 61 (46–72) years) were referred for suspected limb lymphedema to an exclusively lymphedema-dedicated department for a first consultation (January – March 2015) were included; among 118 with upper limb involvement, 100 (84.7%) were diagnosed with post-breast cancer therapy and four with primary lymphedemas; among 136 with lower limb involvement, 31 (22.8%) were diagnosed with primary lymphedemas and 35 (25.7%) with post-cancer lymphedemas. The main alternative diagnoses were: 32 (45.7%) lipedemas/lipo-lymphedemas and 21 (30%) chronic venous insufficiencies. Age at symptom onset, body mass index, referral origins and first-symptom-to-specialized-consultation intervals differed between primary, post-cancer lymphedema and alternative diagnosis patients. Among the entire cohort, 57 (22.4%) had cellulitis. For all 135 (53.1%) upper or lower limb post-cancer lymphedemas and the 119 (46.9%) others, the median (Q1–Q3) first-symptom-to-specialized-consultation intervals were 1.4 (0.7–3.8) and 4 (1.1–18.8) years, respectively ( p < 0.0001). Specialized consultations confirmed primary and post-cancer lymphedema diagnoses and identified others, especially for patients with suspected lower limb lymphedema.

The Evolving Role of Aromatase Inhibitors in Adjuvant Breast Cancer Therapy

2005 ◽  
Vol 6 (3) ◽  
pp. 206-215 ◽  
Author(s):  
I. Craig Henderson ◽  
Martine J. Piccart-Gebhart
Keyword(s):  
Breast Cancer ◽  
Cancer Therapy ◽  
Aromatase Inhibitors ◽  
Breast Cancer Therapy ◽  
Adjuvant Breast Cancer

scholarly journals Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol

2016 ◽  
Vol 37 (21) ◽  
pp. 1671-1680 ◽  
Author(s):  
Geeta Gulati ◽  
Siri Lagethon Heck ◽  
Anne Hansen Ree ◽  
Pavel Hoffmann ◽  
Jeanette Schulz-Menger ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Trial ◽  
Cancer Therapy ◽  
Cardiac Dysfunction ◽  
Breast Cancer Therapy ◽  
Double Blind ◽  
Double Blind Clinical Trial ◽  
Adjuvant Breast Cancer

Adjuvant breast cancer therapy impairs cognitive function

1999 ◽  
Vol &NA; (742) ◽  
pp. 4
Author(s):  
&NA;
Keyword(s):  
Breast Cancer ◽  
Cognitive Function ◽  
Cancer Therapy ◽  
Breast Cancer Therapy ◽  
Adjuvant Breast Cancer

Adjuvant breast cancer therapy

1996 ◽  
Vol 63 (1) ◽  
pp. 9-9
Keyword(s):  
Breast Cancer ◽  
Cancer Therapy ◽  
Breast Cancer Therapy ◽  
Adjuvant Breast Cancer

scholarly journals Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work?

2011 ◽  
Vol 129 (3) ◽  
pp. 799-807 ◽  
Author(s):  
Uwe Güth ◽  
Mary Elizabeth Myrick ◽  
Andreas Schötzau ◽  
Nerbil Kilic ◽  
Seraina Margaretha Schmid
Keyword(s):  
Breast Cancer ◽  
Side Effects ◽  
Cancer Therapy ◽  
Breast Cancer Therapy ◽  
Adverse Side Effects ◽  
Adjuvant Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document